YAP1 and hepatocellular carcinoma: In addition, dihydroartemisinin promoted farnesoid X receptor (FXR) and decreased cholesterol 7 α-hydroxylase (CYP7A1) and YAP1, thus inhibiting bile acid metabolism in HCC.